Deferoxamine mesylate for injection

Meets the RLD EU, US InvoKana, Ready for tech transfer, Dossier readiness Q2 2027

RLD : Motpply XR US
Tech Transfer Readiness- Q2 2027

Under development, The RLD used is Vraylar, Tech transfer readiness Q4 2026, Dossier readiness Q3 2027

RLD used is Zambon and product is available for out-licensing in EU countries and Brazil

Meets the RLD Heptral and Ready for tech transfer, Dossier readiness Q2 2027

Deferasirox Sprinkle granules were developed to improve palatability and patient adherence.
and it is in compliance to EU RLD Jadenu
Dossier Ready for ROW and emerging markets
Dossier Ready for EU- Q2 2027

Ertugliflozin tablets, marketed under the brand names STEGLATRO, STEGLUJAN, and SEGLUROMET, is still under development.

Rare disease product
Developed in India, a generic version of Endari approved in US

Dossier ready for emerging Markets
Will undergo clinical Trials for sickle cell in Q3 2026

Meets the Japan RLD Kremezin granules, worldwide charcoal tablets are already available. The carbon in granule form is more easy to use
Dossier Readiness Q4 2026

Suxibuzone is an analgesic used for joint and muscular pain. It is a prodrug of the non-steroidal anti-inflammatory drug (NSAID) phenylbutazone,

RLD is Renvela (Genzyme). It is open for outlicensing for EU, Canada, Australia and Emerging countries. 

RLD is Renvela (Genzyme). It is open for outlicensing for EU, Canada, Australia and Emerging countries. 

Rajah Dubey, Chief Technical Strategist of SRS Life Sciences, speaks with CPHI TV at CPHI Worldwide in Madrid.